cardiovascular diseases: novel drug, old approach - Hi friends, I hope you are all in good healthMEDIA SERAQUEE, In the article you are reading this time with the title cardiovascular diseases: novel drug, old approach, We have prepared this article well for you to read and take information in it. hopefully the contents of the post Artikel book, Artikel CVDs, Artikel evolocumab, Artikel statins, what we write you can understand. ok, happy reading.

Title : cardiovascular diseases: novel drug, old approach
link : cardiovascular diseases: novel drug, old approach

cardiovascular diseases: novel drug, old approach

I read with interest the news on evolocumab and a large international trial on 27,000 patients.
The British Heart Foundation said the findings were a significant advance in fighting the biggest killer in the world.
 The study found that for every 74 people who took the drug for two years, one heart attack or stroke would be prevented. However, the findings, published in the New England Journal of Medicine, found that the drug had no impact on the rate of cardiovascular mortality.

 Looking for a new drug to lower LDL is a sign that quite few people have now accepted that statins do not work...but addressing CVDs from the same point of view (i.e. LDL) is the fundamental problem as described here and here.


So, are we still at square one?
I am afraid we are...as long we believe that LDL is the problem...
A novel approach is badly needed...
 (an approach that we describe in the book we are writing...)

That's the article cardiovascular diseases: novel drug, old approach

That's it for the article cardiovascular diseases: novel drug, old approach this time, hopefully can be useful for all of you. okay, see you in another article post.

You are now reading the article cardiovascular diseases: novel drug, old approach with link address https://trensnviral.blogspot.com/2017/03/cardiovascular-diseases-novel-drug-old.html